Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim Pharmaceuticals (BIPI) and Eli Lilly have made available their Jardiance (empagliflozin) tablets by prescription in pharmacies across the US, including Walgreens, Rite Aid, Kroger and many other chain and independent retailers.
Subscribe to our email newsletter
Jardiance, a once-daily, 10mg or 25mg tablet, was approved by the US Food and Drug Administration (FDA) on 1 August 2014 as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes.
The drug is not indicated for people with type 1 diabetes or for people with diabetic ketoacidosis.
Boehringer Ingelheim Pharmaceuticals senior vice-president of marketing Kathleen Dowd said: "We believe Jardiance is an exciting new treatment option with the potential to help many of the millions of adults with type 2 diabetes who have difficulty controlling their blood sugar levels."
The sodium glucose co-transporter-2 (SGLT2) inhibitor, Jardiance blocks the reabsorption of glucose in the kidney, which results in the increase of glucose excretion and reduction of blood glucose levels in adults with type 2 diabetes who have elevated blood glucose levels.
Patients with severe kidney problems or are on dialysis, or if they are allergic to empagliflozin or any ingredient in the drug, are suggested not to take Jardiance.
The FDA approval was based on results from a Phase III clinical program which included over ten multinational clinical trials and more than 13,000 adults with type 2 diabetes.
The trials showed that the drug reduced hemoglobin A1C after 24 weeks as a stand-alone treatment or in combination with a range of background treatments, including metformin, sulfonylureas, insulin and pioglitazone.